Sedmak Gerald, Bina David, MacDonald Jeffrey
Virology Division, City of Milwaukee Health Department, Milwaukee, Wisconsin 53202, USA.
Appl Environ Microbiol. 2003 Dec;69(12):7181-7. doi: 10.1128/AEM.69.12.7181-7187.2003.
The quantity and serotypes of enteroviruses (EVs) in the influent of a local sewage treatment plant were compared to local clinical EV cases to determine if testing of sewage is adequate for an EV surveillance system. The study was carried out from August 1994 to December 2002. Monthly influent specimens were processed by organic flocculation, and dilutions of concentrate were inoculated onto a number of different cell types for virus isolation. EVs were detected in 88 of 100 monthly influent samples. Sewage EV titers were calculated by using software provided by the U.S. Environmental Protection Agency for most-probable-number determination. All 1,068 sewage EV isolates were further grouped (echovirus, coxsackievirus B, coxsackievirus A, or poliovirus) by cell culture host range analysis (growth pattern of isolates on passage to seven cell lines), and 39.0% of the 1,022 EV isolates categorized as non-poliovirus EVs were specifically serotyped. For clinical cases, primary virus isolation tests were performed on specimens submitted by local hospitals and EV isolates submitted by hospitals were serotyped. Clinical EVs were documented for 81 of the 100 months studied. In all, 694 EV isolates from clinical cases were serotyped. Annually, between 4 and 11 different serotypes of non-poliovirus EVs were identified in sewage and from 9 to 19 different non-poliovirus EV serotypes were identified from clinical specimens. Usually, the most commonly detected sewage EV serotypes were similar to the most commonly detected clinical serotypes; e.g., for 1997, echovirus 6 accounted for 53.1% of the typed sewage isolates and 39.4% of the clinical infections, while in 1998, echovirus 30 accounted for 50.0 and 46.1%, respectively. In 1999, 60.3% of the EVs from clinical cases and 79.7% of the sewage isolates were echovirus 11; in 2000, 33.3% of the EVs from clinical cases and 40.7% of the sewage isolates were coxsackievirus B5; and in 2001, 44.1% of the EVs from clinical cases and 36.2% of the sewage isolates were echovirus 13. Annual peaks of both sewage EV titers and clinical cases occurred in late summer or early fall. In some years, early spring sewage EVs portended some of the EVs that would predominate clinically during the following summer.
将当地污水处理厂进水口的肠道病毒(EV)数量和血清型与当地临床EV病例进行比较,以确定污水检测对于EV监测系统是否足够。该研究于1994年8月至2002年12月进行。每月的进水样本通过有机絮凝法处理,浓缩液的稀释液接种到多种不同细胞类型上进行病毒分离。100个月度进水样本中有88个检测到了EV。污水EV滴度通过使用美国环境保护局提供的软件进行最可能数测定来计算。所有1068株污水EV分离株通过细胞培养宿主范围分析(分离株在传代至七种细胞系上的生长模式)进一步分组(埃可病毒、柯萨奇病毒B、柯萨奇病毒A或脊髓灰质炎病毒),在1022株分类为非脊髓灰质炎病毒EV的分离株中,39.0%进行了具体血清型鉴定。对于临床病例,对当地医院提交的样本进行了初次病毒分离试验,并对医院提交的EV分离株进行了血清型鉴定。在研究的100个月中有81个月记录到了临床EV。总共对694株临床病例的EV分离株进行了血清型鉴定。每年,在污水中鉴定出4至11种不同血清型的非脊髓灰质炎病毒EV,从临床样本中鉴定出9至19种不同的非脊髓灰质炎病毒EV血清型。通常,污水中最常检测到的EV血清型与临床中最常检测到的血清型相似;例如,1997年,埃可病毒6占已分型污水分离株的53.1%和临床感染的39.4%,而1998年,埃可病毒30分别占50.0%和46.1%。1999年,临床病例中的EV有60.3%和污水分离株有79.7%是埃可病毒11;2000年,临床病例中的EV有33.3%和污水分离株有40.7%是柯萨奇病毒B5;2001年,临床病例中的EV有44.1%和污水分离株有36.2%是埃可病毒13。污水EV滴度和临床病例的年度峰值都出现在夏末或初秋。在某些年份,早春的污水EV预示着随后夏季临床上将占主导的一些EV。